Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | 4-year update of MURANO: venR shows sustained PFS and OS benefits versus BR

John Seymour • 7 Dec 2019
ASH 2019
Chronic Lymphocytic Leukemia Leukemia Antibodies Bendamustine Rituximab Venetoclax
MURANO

John Seymour, MBBS, PhD, FRACP, Peter MacCallum Cancer Centre, Melbourne, Australia, presents a 4-year update of the MURANO study (NCT02005471) which has shown durable responses in patients treated with venetoclax and rituximab (venR) compared to bendamustine and rixutimab (BR). Prof. Seymour discusses an analysis of retreatment as well. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from John Seymour

3:32
BGB-16673, a novel BTK degrader, in patients with R/R B-cell malignancies
John Seymour • 8 Dec 2023
2:18
Efficacy of subsequent therapies for CLL patients treated in the MURANO trial
John Seymour • 8 Dec 2023
3:54
CLL advances: What will we see more of in 2021?
John Seymour • 7 Dec 2020
8:04
The MURANO study in CLL: 5 years on
John Seymour • 7 Dec 2020

Related Videos

1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
2:25
Optimizing haplo-SCT for the treatment of AML
Arnon Nagler • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals